As of 2026-06-24, the EV/EBITDA ratio of Medipharm Labs Corp (LABS.TO) is -2.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LABS.TO's latest enterprise value is 19.89 mil CAD. LABS.TO's TTM EBITDA according to its financial statements is -8.94 mil CAD. Dividing these 2 quantities gives us the above LABS.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.0x - 17.6x | 14.8x |
| Forward P/E multiples | 16.5x - 20.2x | 18.4x |
| Fair Price | (0.32) - (0.35) | (0.33) |
| Upside | -563.6% - -596.7% | -565.2% |
| Date | EV/EBITDA |
| 2026-06-22 | -2.22 |
| 2026-06-19 | -2.22 |
| 2026-06-18 | -2.22 |
| 2026-06-17 | -2.22 |
| 2026-06-16 | -2.46 |
| 2026-06-15 | -2.22 |
| 2026-06-12 | -2.46 |
| 2026-06-11 | -2.22 |
| 2026-06-10 | -2.22 |
| 2026-06-09 | -2.46 |
| 2026-06-08 | -2.46 |
| 2026-06-05 | -2.22 |
| 2026-06-04 | -2.46 |
| 2026-06-03 | -2.46 |
| 2026-06-02 | -2.70 |
| 2026-06-01 | -2.46 |
| 2026-05-29 | -2.46 |
| 2026-05-28 | -2.46 |
| 2026-05-27 | -2.70 |
| 2026-05-26 | -2.70 |
| 2026-05-25 | -2.70 |
| 2026-05-22 | -2.70 |
| 2026-05-21 | -2.70 |
| 2026-05-20 | -2.70 |
| 2026-05-19 | -2.70 |
| 2026-05-15 | -2.94 |
| 2026-05-14 | -2.94 |
| 2026-05-13 | -3.17 |
| 2026-05-12 | -2.70 |
| 2026-05-11 | -2.94 |
| 2026-05-08 | -2.94 |
| 2026-05-07 | -3.17 |
| 2026-05-06 | -2.94 |
| 2026-05-05 | -2.94 |
| 2026-05-04 | -2.94 |
| 2026-05-01 | -3.17 |
| 2026-04-30 | -3.17 |
| 2026-04-29 | -3.17 |
| 2026-04-28 | -3.17 |
| 2026-04-27 | -2.46 |
| 2026-04-24 | -1.99 |
| 2026-04-23 | -2.22 |
| 2026-04-22 | -2.22 |
| 2026-04-21 | -1.99 |
| 2026-04-20 | -1.99 |
| 2026-04-17 | -1.99 |
| 2026-04-16 | -1.99 |
| 2026-04-15 | -1.99 |
| 2026-04-14 | -1.99 |
| 2026-04-13 | -1.99 |